A Phase 1 interventional study of PL54 in Phenylketonuria (PKU), sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this clinical trial is to evaluate the safety and tolerability of single and multiple administrations of PL54 in patients aged 18-55 years. The key questions it aims to answer include:
How safe and tolerable is PL54 in PKU patients following single and multiple administrations?
Researchers will compare the safety and tolerability profiles between single and multiple dosing regimens to assess PL54.
Participants will be required to:
Phase Ia (Single Administration):
Receive a single subcutaneous injection of PL54 based on body weight. Undergo a 28-day observation period post-injection. Visit the clinic for assessments on: D1 (administration day), D2, D7, D8, D10, D15, D22, and D29.
Phase Ib (Multiple Administrations):
Receive subcutaneous injections of PL54 every 7 days (4 doses total) based on body weight. Undergo a 35-day observation period after the last injection. Visit the clinic for assessments on: D1 (first administration), D3, D8, D15, D21, D22, D29, D36, D43, and D57
Data to be recorded include:
Incidence, severity, seriousness, relationship to PL54 treatment, duration, and outcome of adverse events (AEs).
Change from baseline in blood phenylalanine (Phe) concentration.
This is a multicenter, open-label, dose-escalation Phase I clinical study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single or multiple subcutaneous injections of PL54 injection in adult patients with phenylketonuria (PKU). The trial is divided into Phase Ia and Phase Ib.
Phase Ia:
A single subcutaneous injection will be administered. The phase includes a 2-week screening period, a single administration on Day 1 (D1), and a 4-week follow-up period, totaling approximately 6 weeks. Approximately 30 subjects will be enrolled across five dose groups: 0.01 mg/kg, 0.04 mg/kg, 0.1 mg/kg, 0.25 mg/kg, and 0.5 mg/kg, with 6 subjects per group (including 1 sentinel). The first subject in each dose group will receive a single subcutaneous injection of PL54, and the remaining subjects in the same dose group will be enrolled only after the first subject has completed at least 14 days of safety assessment. Dose escalation to the next group will proceed only after all subjects in the previous dose group have completed at least 14 days of visit assessments and the Safety Monitoring Committee (SMC) determines that the dose escalation termination criteria have not been met.
Phase Ib:
Approximately 18 subjects will be enrolled. Subcutaneous injections will be administered once weekly for 4 consecutive weeks (the dosing period for subsequent dose groups may be adjusted based on observed anti-drug antibody [ADA], pharmacokinetic [PK], and pharmacodynamic [PD] results from previous dose groups). Three dose groups are planned: 0.04 mg/kg, 0.1 mg/kg, and 0.25 mg/kg, with 6 subjects per group (the actual dose groups and dosing regimen will be adjusted based on Phase Ia results). Dose escalation to the next group will proceed only after all subjects in the previous dose group have completed at least 28 days of visit assessments and the SMC determines that the dose escalation termination criteria have not been met.
191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.
This study's planned enrollment of 48 is above the median of 27 across 122 interventional studies indexed under Phenylketonurias.
Browse Phenylketonurias studies →Chongqing Peg-Bio Biopharm Co., Ltd. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Subjects with a prior diagnosis of phenylketonuria (PKU) meeting the following criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subcutaneous injection administration. Single -dose escalation will start from the initial dose of 0.01 mg/kg and proceed sequentially to higher doses.
Biological: PL54
Phase Ia: Single, subcutaneous injection administration. Dose escalation will start from the initial dose of 0.01 mg/kg and proceed sequentially to higher doses. Phase Ib: Administration via subcutaneous injection. Dosing frequency: once weekly. Dose escalation will start from the initial dose of 0.04 mg/kg and proceed sequentially to higher doses.
Also known as: PEGylated Recombinant Phenylalanine Ammonia-Lyase
Adverse Events (AEs)
including the incidence of overall and categorized AEs
Time frame: Day 1-29 of Phase Ia; Day 1-57 of Phase Ib
The change in blood phenylalanine concentration from baseline
Comparing the average phenylalanine concentrations at different timepoints and different doses with the concentration at baseline in Phase Ia and Phase Ib studies.
Time frame: Day 1-29 of Phase Ia; Day 1-57 of Phase Ib
The proportion of subjects whose blood phenylalanine concentration decreased to the target range (60-600 μmol/L)
Monitor the blood phenylalanine concentration at each visit and calculate the proportion of subjects whose phenylalanine concentration drops to the target range (60-600 μ mol/L) for each dose group in Phase Ia and Phase Ib studies.
Time frame: Day 1-29 of Phase Ia; Day 1-57 of Phase Ib
PK parameters of PL54 after single dose and multiple doses
Calculate the following PK parameters, including but not limited to Cmax, Tmax, AUC0-t, AUC0-∞, T1/2, λz, CL/F, Vz/F for Phase Ia, and AUC0-τ, Cmin,ss, Cmax,ss, Tmax,ss, T1/2 for Phase Ib.
Time frame: Day 1-29 of Phase Ia; Day 1-57 of Phase Ib
Immunogenicity of PL54
Total anti-drug antibodies (if applicable), anti-PAL4 antibodies, anti-PEG IgG/IgM, neutralizing antibodies that inhibit PL54 activity (NAbs), and detection of anti-PL54 IgE antibodies in subjects experiencing severe allergic reactions (WAO criteria).
Time frame: Day 1-29 of Phase Ia; Day 1-57 of Phase Ib
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chongqing Peg-Bio Biopharm Co., Ltd. →